Aurora Cannabis Inc.
Aurora Cannabis Inc. ACB Peers
See (ACB) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ACB | $4.54 | +1.57% | 255.4M | 23.89 | $0.19 | N/A |
| ZTS | $159.18 | +0.06% | 70.9B | 28.63 | $5.56 | +1.17% |
| TAK | $15.34 | -0.52% | 48.3B | 66.70 | $0.23 | +3.84% |
| HLN | $10.25 | -0.10% | 46.1B | 23.84 | $0.43 | +1.14% |
| TEVA | $17.01 | -0.23% | 19.5B | -14.79 | -$1.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $129.11 | -0.22% | 12.8B | 43.77 | $2.95 | N/A |
| RDY | $15.08 | +1.34% | 12.5B | 19.33 | $0.78 | +0.64% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RGC | $22.99 | +121.91% | 11.4B | -2299.00 | -$0.01 | N/A |
Stock Comparison
ACB vs ZTS Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ZTS has a market cap of 70.9B. Regarding current trading prices, ACB is priced at $4.54, while ZTS trades at $159.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ZTS's P/E ratio is 28.63. In terms of profitability, ACB's ROE is +0.00%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, ACB is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs TAK Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, TAK has a market cap of 48.3B. Regarding current trading prices, ACB is priced at $4.54, while TAK trades at $15.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas TAK's P/E ratio is 66.70. In terms of profitability, ACB's ROE is +0.00%, compared to TAK's ROE of +0.04%. Regarding short-term risk, ACB is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs HLN Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, HLN has a market cap of 46.1B. Regarding current trading prices, ACB is priced at $4.54, while HLN trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas HLN's P/E ratio is 23.84. In terms of profitability, ACB's ROE is +0.00%, compared to HLN's ROE of +0.09%. Regarding short-term risk, ACB is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs TEVA Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, TEVA has a market cap of 19.5B. Regarding current trading prices, ACB is priced at $4.54, while TEVA trades at $17.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas TEVA's P/E ratio is -14.79. In terms of profitability, ACB's ROE is +0.00%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, ACB is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs ITCI Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ACB is priced at $4.54, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ACB's ROE is +0.00%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, ACB is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs NBIX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, NBIX has a market cap of 12.8B. Regarding current trading prices, ACB is priced at $4.54, while NBIX trades at $129.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas NBIX's P/E ratio is 43.77. In terms of profitability, ACB's ROE is +0.00%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, ACB is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs RDY Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, RDY has a market cap of 12.5B. Regarding current trading prices, ACB is priced at $4.54, while RDY trades at $15.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas RDY's P/E ratio is 19.33. In terms of profitability, ACB's ROE is +0.00%, compared to RDY's ROE of +0.18%. Regarding short-term risk, ACB is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs CTLT Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ACB is priced at $4.54, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ACB's ROE is +0.00%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, ACB is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs RGC Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, RGC has a market cap of 11.4B. Regarding current trading prices, ACB is priced at $4.54, while RGC trades at $22.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas RGC's P/E ratio is -2299.00. In terms of profitability, ACB's ROE is +0.00%, compared to RGC's ROE of -0.25%. Regarding short-term risk, ACB is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs VTRS Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, VTRS has a market cap of 10.9B. Regarding current trading prices, ACB is priced at $4.54, while VTRS trades at $9.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas VTRS's P/E ratio is -2.93. In terms of profitability, ACB's ROE is +0.00%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, ACB is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs ELAN Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ELAN has a market cap of 7.3B. Regarding current trading prices, ACB is priced at $4.54, while ELAN trades at $14.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ELAN's P/E ratio is 19.52. In terms of profitability, ACB's ROE is +0.00%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, ACB is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs LNTH Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, LNTH has a market cap of 5.6B. Regarding current trading prices, ACB is priced at $4.54, while LNTH trades at $80.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas LNTH's P/E ratio is 22.91. In terms of profitability, ACB's ROE is +0.00%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ACB is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs AMRX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, AMRX has a market cap of 3.9B. Regarding current trading prices, ACB is priced at $4.54, while AMRX trades at $8.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas AMRX's P/E ratio is -210.50. In terms of profitability, ACB's ROE is +0.00%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, ACB is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs PRGO Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, PRGO has a market cap of 3.7B. Regarding current trading prices, ACB is priced at $4.54, while PRGO trades at $27.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas PRGO's P/E ratio is -22.67. In terms of profitability, ACB's ROE is +0.00%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, ACB is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs ALVO Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ALVO has a market cap of 2.8B. Regarding current trading prices, ACB is priced at $4.54, while ALVO trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ALVO's P/E ratio is 24.84. In terms of profitability, ACB's ROE is +0.00%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, ACB is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs ALVOW Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ALVOW has a market cap of 2.8B. Regarding current trading prices, ACB is priced at $4.54, while ALVOW trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ALVOW's P/E ratio is N/A. In terms of profitability, ACB's ROE is +0.00%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, ACB is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs HCM Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, HCM has a market cap of 2.8B. Regarding current trading prices, ACB is priced at $4.54, while HCM trades at $15.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas HCM's P/E ratio is 79.05. In terms of profitability, ACB's ROE is +0.00%, compared to HCM's ROE of +0.05%. Regarding short-term risk, ACB is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs BHC Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, BHC has a market cap of 2.6B. Regarding current trading prices, ACB is priced at $4.54, while BHC trades at $7.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas BHC's P/E ratio is -58.83. In terms of profitability, ACB's ROE is +0.00%, compared to BHC's ROE of +0.05%. Regarding short-term risk, ACB is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs DCPH Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ACB is priced at $4.54, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ACB's ROE is +0.00%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, ACB is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs INDV Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, INDV has a market cap of 1.9B. Regarding current trading prices, ACB is priced at $4.54, while INDV trades at $15.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas INDV's P/E ratio is -308.20. In terms of profitability, ACB's ROE is +0.00%, compared to INDV's ROE of -0.01%. Regarding short-term risk, ACB is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs EMBCV Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ACB is priced at $4.54, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ACB's ROE is +0.00%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, ACB is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs BGM Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, BGM has a market cap of 1.8B. Regarding current trading prices, ACB is priced at $4.54, while BGM trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas BGM's P/E ratio is -50.15. In terms of profitability, ACB's ROE is +0.00%, compared to BGM's ROE of -0.03%. Regarding short-term risk, ACB is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs SUPN Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, SUPN has a market cap of 1.8B. Regarding current trading prices, ACB is priced at $4.54, while SUPN trades at $31.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas SUPN's P/E ratio is 28.81. In terms of profitability, ACB's ROE is +0.00%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, ACB is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs TARO Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ACB is priced at $4.54, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas TARO's P/E ratio is 30.05. In terms of profitability, ACB's ROE is +0.00%, compared to TARO's ROE of +0.02%. Regarding short-term risk, ACB is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs EVO Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, EVO has a market cap of 1.5B. Regarding current trading prices, ACB is priced at $4.54, while EVO trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas EVO's P/E ratio is -6.27. In terms of profitability, ACB's ROE is +0.00%, compared to EVO's ROE of -0.22%. Regarding short-term risk, ACB is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs ANIP Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, ACB is priced at $4.54, while ANIP trades at $65.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ANIP's P/E ratio is -55.32. In terms of profitability, ACB's ROE is +0.00%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, ACB is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs DVAX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, DVAX has a market cap of 1.2B. Regarding current trading prices, ACB is priced at $4.54, while DVAX trades at $10.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas DVAX's P/E ratio is -20.54. In terms of profitability, ACB's ROE is +0.00%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ACB is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs HROW Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, ACB is priced at $4.54, while HROW trades at $31.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas HROW's P/E ratio is -52.05. In terms of profitability, ACB's ROE is +0.00%, compared to HROW's ROE of -0.36%. Regarding short-term risk, ACB is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs PAHC Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, PAHC has a market cap of 1.1B. Regarding current trading prices, ACB is priced at $4.54, while PAHC trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas PAHC's P/E ratio is 35.90. In terms of profitability, ACB's ROE is +0.00%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, ACB is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs AMPH Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, ACB is priced at $4.54, while AMPH trades at $23.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas AMPH's P/E ratio is 8.41. In terms of profitability, ACB's ROE is +0.00%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, ACB is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs PCRX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, PCRX has a market cap of 1.1B. Regarding current trading prices, ACB is priced at $4.54, while PCRX trades at $23.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas PCRX's P/E ratio is -10.37. In terms of profitability, ACB's ROE is +0.00%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, ACB is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs COLL Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, COLL has a market cap of 975.5M. Regarding current trading prices, ACB is priced at $4.54, while COLL trades at $30.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas COLL's P/E ratio is 24.88. In terms of profitability, ACB's ROE is +0.00%, compared to COLL's ROE of +0.19%. Regarding short-term risk, ACB is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs PETQ Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ACB is priced at $4.54, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ACB's ROE is +0.00%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, ACB is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs AVDL Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, AVDL has a market cap of 865.3M. Regarding current trading prices, ACB is priced at $4.54, while AVDL trades at $8.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas AVDL's P/E ratio is -34.35. In terms of profitability, ACB's ROE is +0.00%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, ACB is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs CRON Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, CRON has a market cap of 786.3M. Regarding current trading prices, ACB is priced at $4.54, while CRON trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas CRON's P/E ratio is 14.57. In terms of profitability, ACB's ROE is +0.00%, compared to CRON's ROE of +0.05%. Regarding short-term risk, ACB is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs EMBC Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, EMBC has a market cap of 603.1M. Regarding current trading prices, ACB is priced at $4.54, while EMBC trades at $10.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas EMBC's P/E ratio is 11.60. In terms of profitability, ACB's ROE is +0.00%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, ACB is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs EOLS Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, EOLS has a market cap of 597.7M. Regarding current trading prices, ACB is priced at $4.54, while EOLS trades at $9.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas EOLS's P/E ratio is -10.42. In terms of profitability, ACB's ROE is +0.00%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, ACB is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs BDSI Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ACB is priced at $4.54, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ACB's ROE is +0.00%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ACB is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs TLRY Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, TLRY has a market cap of 559.2M. Regarding current trading prices, ACB is priced at $4.54, while TLRY trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas TLRY's P/E ratio is -0.51. In terms of profitability, ACB's ROE is +0.00%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, ACB is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs ORGO Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ORGO has a market cap of 539.1M. Regarding current trading prices, ACB is priced at $4.54, while ORGO trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ORGO's P/E ratio is -26.56. In terms of profitability, ACB's ROE is +0.00%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, ACB is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs SIGA Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, SIGA has a market cap of 477.9M. Regarding current trading prices, ACB is priced at $4.54, while SIGA trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas SIGA's P/E ratio is 9.99. In terms of profitability, ACB's ROE is +0.00%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, ACB is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs KMDA Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, KMDA has a market cap of 453.1M. Regarding current trading prices, ACB is priced at $4.54, while KMDA trades at $7.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas KMDA's P/E ratio is 28.14. In terms of profitability, ACB's ROE is +0.00%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, ACB is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs EBS Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, EBS has a market cap of 379.4M. Regarding current trading prices, ACB is priced at $4.54, while EBS trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas EBS's P/E ratio is -2.71. In terms of profitability, ACB's ROE is +0.00%, compared to EBS's ROE of -0.27%. Regarding short-term risk, ACB is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs AQST Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, AQST has a market cap of 369.5M. Regarding current trading prices, ACB is priced at $4.54, while AQST trades at $3.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas AQST's P/E ratio is -6.41. In terms of profitability, ACB's ROE is +0.00%, compared to AQST's ROE of +1.07%. Regarding short-term risk, ACB is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs SNDL Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, SNDL has a market cap of 326.8M. Regarding current trading prices, ACB is priced at $4.54, while SNDL trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas SNDL's P/E ratio is -4.23. In terms of profitability, ACB's ROE is +0.00%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, ACB is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs ALIM Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ACB is priced at $4.54, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ACB's ROE is +0.00%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, ACB is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs LFCR Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, LFCR has a market cap of 297.7M. Regarding current trading prices, ACB is priced at $4.54, while LFCR trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas LFCR's P/E ratio is -5.47. In terms of profitability, ACB's ROE is +0.00%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, ACB is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs ZYBT Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ZYBT has a market cap of 286.7M. Regarding current trading prices, ACB is priced at $4.54, while ZYBT trades at $6.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ZYBT's P/E ratio is 100.83. In terms of profitability, ACB's ROE is +0.00%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, ACB is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs TKNO Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, TKNO has a market cap of 278.4M. Regarding current trading prices, ACB is priced at $4.54, while TKNO trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas TKNO's P/E ratio is -11.33. In terms of profitability, ACB's ROE is +0.00%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, ACB is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs CGC Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, CGC has a market cap of 265.8M. Regarding current trading prices, ACB is priced at $4.54, while CGC trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas CGC's P/E ratio is -0.31. In terms of profitability, ACB's ROE is +0.00%, compared to CGC's ROE of -1.13%. Regarding short-term risk, ACB is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs LNDC Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ACB is priced at $4.54, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ACB's ROE is +0.00%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, ACB is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs ESPR Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ESPR has a market cap of 231.9M. Regarding current trading prices, ACB is priced at $4.54, while ESPR trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ESPR's P/E ratio is -1.38. In terms of profitability, ACB's ROE is +0.00%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, ACB is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs TYHT Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ACB is priced at $4.54, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ACB's ROE is +0.00%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, ACB is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs OGI Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, OGI has a market cap of 191.5M. Regarding current trading prices, ACB is priced at $4.54, while OGI trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas OGI's P/E ratio is 11.00. In terms of profitability, ACB's ROE is +0.00%, compared to OGI's ROE of +0.05%. Regarding short-term risk, ACB is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs REPH Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ACB is priced at $4.54, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas REPH's P/E ratio is -8.04. In terms of profitability, ACB's ROE is +0.00%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ACB is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs DERM Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, DERM has a market cap of 165.4M. Regarding current trading prices, ACB is priced at $4.54, while DERM trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas DERM's P/E ratio is -19.19. In terms of profitability, ACB's ROE is +0.00%, compared to DERM's ROE of -0.52%. Regarding short-term risk, ACB is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs BIOA Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, BIOA has a market cap of 153.4M. Regarding current trading prices, ACB is priced at $4.54, while BIOA trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas BIOA's P/E ratio is -2.16. In terms of profitability, ACB's ROE is +0.00%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, ACB is more volatile compared to BIOA. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs THTX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, THTX has a market cap of 147.1M. Regarding current trading prices, ACB is priced at $4.54, while THTX trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas THTX's P/E ratio is -45.71. In terms of profitability, ACB's ROE is +0.00%, compared to THTX's ROE of +0.16%. Regarding short-term risk, ACB is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs CRDL Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, CRDL has a market cap of 127.3M. Regarding current trading prices, ACB is priced at $4.54, while CRDL trades at $1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas CRDL's P/E ratio is -4.53. In terms of profitability, ACB's ROE is +0.00%, compared to CRDL's ROE of -2.08%. Regarding short-term risk, ACB is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs IRWD Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, IRWD has a market cap of 124M. Regarding current trading prices, ACB is priced at $4.54, while IRWD trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas IRWD's P/E ratio is -4.03. In terms of profitability, ACB's ROE is +0.00%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, ACB is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs SCTL Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ACB is priced at $4.54, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ACB's ROE is +0.00%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ACB is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs PROC Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, PROC has a market cap of 114M. Regarding current trading prices, ACB is priced at $4.54, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas PROC's P/E ratio is 1.53. In terms of profitability, ACB's ROE is +0.00%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ACB is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs OPTN Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ACB is priced at $4.54, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ACB's ROE is +0.00%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, ACB is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs ZOM Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ACB is priced at $4.54, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ACB's ROE is +0.00%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, ACB is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs GRVI Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ACB is priced at $4.54, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ACB's ROE is +0.00%, compared to GRVI's ROE of -5.25%. Regarding short-term risk, ACB is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs INCR Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, INCR has a market cap of 73.6M. Regarding current trading prices, ACB is priced at $4.54, while INCR trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas INCR's P/E ratio is -3.63. In terms of profitability, ACB's ROE is +0.00%, compared to INCR's ROE of -0.07%. Regarding short-term risk, ACB is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs ZYNE Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ACB is priced at $4.54, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ACB's ROE is +0.00%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ACB is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs SSIC Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ACB is priced at $4.54, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ACB's ROE is +0.00%, compared to SSIC's ROE of +0.03%. Regarding short-term risk, ACB is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs ASRT Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ASRT has a market cap of 62.5M. Regarding current trading prices, ACB is priced at $4.54, while ASRT trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ASRT's P/E ratio is -2.04. In terms of profitability, ACB's ROE is +0.00%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, ACB is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs VLNS Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ACB is priced at $4.54, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ACB's ROE is +0.00%, compared to VLNS's ROE of N/A. Regarding short-term risk, ACB is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs QNTM Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, QNTM has a market cap of 49.6M. Regarding current trading prices, ACB is priced at $4.54, while QNTM trades at $17.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas QNTM's P/E ratio is -1.29. In terms of profitability, ACB's ROE is +0.00%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, ACB is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs JUPW Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ACB is priced at $4.54, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ACB's ROE is +0.00%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, ACB is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs SXTC Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, SXTC has a market cap of 48.9M. Regarding current trading prices, ACB is priced at $4.54, while SXTC trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas SXTC's P/E ratio is 0.02. In terms of profitability, ACB's ROE is +0.00%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, ACB is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs CPIX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, CPIX has a market cap of 47.1M. Regarding current trading prices, ACB is priced at $4.54, while CPIX trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas CPIX's P/E ratio is -13.12. In terms of profitability, ACB's ROE is +0.00%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, ACB is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs EGRX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, EGRX has a market cap of 38.9M. Regarding current trading prices, ACB is priced at $4.54, while EGRX trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas EGRX's P/E ratio is 3.53. In terms of profitability, ACB's ROE is +0.00%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, ACB is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs QLI Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ACB is priced at $4.54, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas QLI's P/E ratio is -4.92. In terms of profitability, ACB's ROE is +0.00%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ACB is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs KALA Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, KALA has a market cap of 32.9M. Regarding current trading prices, ACB is priced at $4.54, while KALA trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas KALA's P/E ratio is -0.69. In terms of profitability, ACB's ROE is +0.00%, compared to KALA's ROE of -3.69%. Regarding short-term risk, ACB is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs HEXO Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ACB is priced at $4.54, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ACB's ROE is +0.00%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ACB is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs SCYX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, SCYX has a market cap of 28.5M. Regarding current trading prices, ACB is priced at $4.54, while SCYX trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas SCYX's P/E ratio is -1.31. In terms of profitability, ACB's ROE is +0.00%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, ACB is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs RMTI Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, RMTI has a market cap of 28.1M. Regarding current trading prices, ACB is priced at $4.54, while RMTI trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas RMTI's P/E ratio is -82.28. In terms of profitability, ACB's ROE is +0.00%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, ACB is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs CYTH Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ACB is priced at $4.54, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ACB's ROE is +0.00%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, ACB is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs DRRX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, DRRX has a market cap of 20.7M. Regarding current trading prices, ACB is priced at $4.54, while DRRX trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas DRRX's P/E ratio is -1.39. In terms of profitability, ACB's ROE is +0.00%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, ACB is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs IXHL Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, IXHL has a market cap of 19.6M. Regarding current trading prices, ACB is priced at $4.54, while IXHL trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas IXHL's P/E ratio is -0.17. In terms of profitability, ACB's ROE is +0.00%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, ACB is more volatile compared to IXHL. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs PRPH Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, PRPH has a market cap of 17.4M. Regarding current trading prices, ACB is priced at $4.54, while PRPH trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas PRPH's P/E ratio is -0.19. In terms of profitability, ACB's ROE is +0.00%, compared to PRPH's ROE of -1.65%. Regarding short-term risk, ACB is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs GELS Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, GELS has a market cap of 16.2M. Regarding current trading prices, ACB is priced at $4.54, while GELS trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas GELS's P/E ratio is -7.17. In terms of profitability, ACB's ROE is +0.00%, compared to GELS's ROE of -0.21%. Regarding short-term risk, ACB is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs AYTU Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, AYTU has a market cap of 14.7M. Regarding current trading prices, ACB is priced at $4.54, while AYTU trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas AYTU's P/E ratio is -1.60. In terms of profitability, ACB's ROE is +0.00%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, ACB is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs ACRX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ACB is priced at $4.54, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ACB's ROE is +0.00%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, ACB is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs TXMD Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, TXMD has a market cap of 13.7M. Regarding current trading prices, ACB is priced at $4.54, while TXMD trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas TXMD's P/E ratio is -6.21. In terms of profitability, ACB's ROE is +0.00%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, ACB is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs FLGC Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, FLGC has a market cap of 13.4M. Regarding current trading prices, ACB is priced at $4.54, while FLGC trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas FLGC's P/E ratio is -0.62. In terms of profitability, ACB's ROE is +0.00%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, ACB is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs COSM Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, COSM has a market cap of 12.4M. Regarding current trading prices, ACB is priced at $4.54, while COSM trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas COSM's P/E ratio is -0.39. In terms of profitability, ACB's ROE is +0.00%, compared to COSM's ROE of -0.51%. Regarding short-term risk, ACB is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs AGRX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ACB is priced at $4.54, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ACB's ROE is +0.00%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, ACB is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs TLPH Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, TLPH has a market cap of 9.2M. Regarding current trading prices, ACB is priced at $4.54, while TLPH trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas TLPH's P/E ratio is -1.02. In terms of profitability, ACB's ROE is +0.00%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, ACB is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs IMCC Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, IMCC has a market cap of 9.1M. Regarding current trading prices, ACB is priced at $4.54, while IMCC trades at $2.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas IMCC's P/E ratio is -2.14. In terms of profitability, ACB's ROE is +0.00%, compared to IMCC's ROE of -1.52%. Regarding short-term risk, ACB is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs SBFMW Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, SBFMW has a market cap of 8.4M. Regarding current trading prices, ACB is priced at $4.54, while SBFMW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas SBFMW's P/E ratio is -0.12. In terms of profitability, ACB's ROE is +0.00%, compared to SBFMW's ROE of -0.21%. Regarding short-term risk, ACB is more volatile compared to SBFMW. This indicates potentially higher risk in terms of short-term price fluctuations for ACB.
ACB vs NLTX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ACB is priced at $4.54, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ACB's ROE is +0.00%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, ACB is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs YCBD Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, YCBD has a market cap of 7.7M. Regarding current trading prices, ACB is priced at $4.54, while YCBD trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas YCBD's P/E ratio is 0.01. In terms of profitability, ACB's ROE is +0.00%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, ACB is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs LCI Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ACB is priced at $4.54, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas LCI's P/E ratio is -0.04. In terms of profitability, ACB's ROE is +0.00%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ACB is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs BGXX Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, ACB is priced at $4.54, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas BGXX's P/E ratio is -0.76. In terms of profitability, ACB's ROE is +0.00%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, ACB is less volatile compared to BGXX. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.
ACB vs ADMP Comparison
ACB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACB stands at 255.4M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ACB is priced at $4.54, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACB currently has a P/E ratio of 23.89, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ACB's ROE is +0.00%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ACB is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for ACB.